The Current Ratio as of November 2024 (TTM) for Gain Therapeutics, Inc. (GANX) is 2.84

According to Gain Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.84. This represents a change of -1.16% compared to the average of 2.88 of the last 4 quarters.

Gain Therapeutics, Inc. (GANX) Historical Current Ratio (quarterly & annually)

How has GANX Current Ratio performed in the past?

The mean historical Current Ratio of Gain Therapeutics, Inc. over the last ten years is 4.86. The current 2.84 Current Ratio has changed 5.75% with respect to the historical average. Over the past ten years (40 quarters), GANX's Current Ratio was at its highest in in the March 2021 quarter at 20.37. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Gain Therapeutics, Inc. (GANX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Gain Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Gain Therapeutics, Inc. (GANX) Average Current Ratio

How has GANX Current Ratio performed in the past?

The current Current Ratio of Gain Therapeutics, Inc. (GANX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Gain Therapeutics, Inc. (GANX) Current Ratio vs. Peers

How is GANX’s Current Ratio compared to its peers?

Gain Therapeutics, Inc.’s Current Ratio is greater than BioVie Inc. (2.57), greater than IN8bio, Inc. (2.66), less than NewAmsterdam Pharma Company N.V. (9.83), greater than Cue Biopharma, Inc. (2.06), greater than TFF Pharmaceuticals, Inc. (1.63), less than aTyr Pharma, Inc. (6.07), less than Lantern Pharma Inc. (7.67), less than Eliem Therapeutics, Inc. (0), less than Inhibrx Biosciences, Inc. (60.41), less than Merrimack Pharmaceuticals, Inc. (6.20), less than Celcuity Inc. (10.78), less than Enliven Therapeutics, Inc. (14.95), less than Molecular Partners AG (14.39), less than MediciNova, Inc. (14.58), less than Anebulo Pharmaceuticals, Inc. (18.24), less than Champions Oncology, Inc. (13.46), greater than Cyteir Therapeutics, Inc. (0.69), less than null (21.89),

Build a custom stock screener for Gain Therapeutics, Inc. (GANX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gain Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gain Therapeutics, Inc. (GANX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gain Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.